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Abstract 
It has been proposed that lithocholic acid may have a physiological role for the regulation of bile acid synthesis in humans. In this 
study, the portal venous concentration and hepatic uptake of unsulfated lithocholic acid was determined in 21 gallstone patients - -  
untreated, cholestyramine-treated an chenodeoxycholic a id-treated - -  at cholecystectomy. Lithocholic acid was analyzed by a 
combined gas-liquid mass-fragmentographic technique. In most of the patients a liver biopsy was obtained for assay of the cholesterol 
7ct-hydroxylase activity. The portal venous concentration of unsulfated lithocholic acid averaged 0.32 txmol/1 in untreated patients, 
constituting about 4% of the total bile acids. The apparent hepatic uptake of lithocholic acid averaged 78%, being as high as that of cholic 
acid. No significant correlation was obtained between the portal venous concentration of unsulfated lithocholic acid and the hepatic 
cholesterol 7et-hydroxylase activity. This study thus confirms an enterohepatic circulation of lithocholic acid in humans. No evidence was 
obtained that the portal venous inflow of small amounts of lithocholic acid to the liver is of regulatory importance for the cholesterol 
7et-hydroxylase activity. 
Keywords: Bile acid; Chenodeoxycholic acid; Cholestyramine; H patic uptake; Mass spectrometry 
1. Introduct ion 
Lithocholic acid is one of the major fecal bile acids in 
man, being formed from chenodeoxycholic a id by micro- 
bial 7ot-dehydroxylation [1,2]. In healthy man about one 
fifth of lithocholic acid formed in the colon is absorbed. 
The absorbed lithocholic acid is returned to the liver being 
conjugated with glycine or taurine, and in contrast o most 
other bile acids also to a high degree being sulfated at the 
3a-hydroxy position, and excreted into bile. Sulfated litho- 
cholic acid is poorly absorbed from the intestine and 
rapidly excreted in the feces. Lithocholic acid is a minor 
bile acid in human bile. The concentration of lithocholic 
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acid in portal venous blood is probably also low but to our 
knowledge it has not previously been determined in hu- 
mans. Neither has the hepatic uptake of lithocholic acid 
been directly measured. 
According to current concepts, the formation of bile 
acids from cholesterol is regulated by the portal venous 
inflow of bile acids [ 1,2]. Not only the total concentration, 
but also the pattern of individual bile acids in the portal 
bk~od is of regulatory importance [3]. It has been claimed 
by some authors that the degree of hydrophobicity of bile 
acids is of major importance, hydrophobic bile acids being 
more efficient suppressors of bile acid synthesis compared 
with more hydrophilic bile acids in rats [4]. Hall et al. [5] 
have given evidence that monohydroxy bile acids in small 
amounts, e.g. unsulfated lithocholic acid which is highly 
hydrophobic, may participate in the regulation of bile acid 
synthesis in rabbits. These authors also proposed that small 
amounts of monohydroxy bile acids e.g. lithocholic acid, 
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may have a physiological role for the regulation of bile 
acid synthesis in humans. 
The present investigation was undertaken to obtain 
more information about enterohepatic circulation of litho- 
cholic acid and its possible physiological role in gallstone 
patients. Specifically, we sought answers to the following 
questions: (a) What are the portal venous concentration 
and hepatic uptake of unsulfated lithocholic acid? (b) Is 
the hepatic inflow of such lithocholic acid of any regula- 
tory importance of the hepatic cholesterol 7ct-hydroxylase 
activity? An assay for serum concentrations of unsulfated 
l i thochol ic  acid with combined  gas- l iquid 
chromatography-mass spectrometry, using 14C-labeled 
lithocholic acid as internal standard, was developed. Sam- 
ples from portal venous and peripheral venous blood of 
gallstone patients undergoing cholecystectomy were ana- 
lyzed. Some patients were treated with cholestyramine or 
chenodeoxycholic a id before operation. In most of the 
patients a peroperative liver biopsy was obtained for assay 
of the cholesterol 7a-hydroxylase activity. 
2. Materials and methods 
2.1. Materials 
Chenodeoxycholic acid (Chenofalk), in 250 mg-capsu- 
las was purchased from Dr. Falk, Pharma (Freiburg, Ger- 
many). Cholestyramine (Questran ®) was obtained from 
Bristol-Myers Squibb Co. (New York, USA). Deuterium- 
labeled bile acids were those used in previous studies 
[7-10]. [24-14 C]lithocholic acid (about 90% purity with 
respect to 14C) was purchased from New England Nuclear 
Corp., Boston, MA, USA. 
2.2. Patients 
Altogether 21 patients, 18 females and 3 males with 
uncomplicated gallstone disease were included in the study 
(Tables 1 and 2). Their mean age was 48 yr (range 22-73) 
and their mean body wt. was 68 kg (range 50-85 kg). One 
of the patients, no 7, was slightly overweight. Four of the 
Table 2 
Serum concentrations of individual bile acids in portal venous blood and cholesterol 7a-hydroxylase activities in liver biopsies of gallstone patients 
Patient CA CDCA DCA UDCA LCA 7a-Hydroxylase activity 
No. Sex Age (yr) (Ixmol/1) (pmol/min per mg protein) 
Untreated: 
I. F 57 8.51 6.38 3.56 0.95 0.49 
2. F 56 1.01 0.66 1.67 ND 0.18 
3. F 66 1.64 1.59 1.96 ND 0.34 
4. F 53 2.62 3.22 3.83 1.06 1.23 
5. M 59 3.30 2.03 2.16 0.32 0.21 
6. F 44 2.30 0.75 ND ND O. 10 
7. F 73 1.60 0.75 1.20 ND 0.20 
8. F 22 6.50 4.45 1.15 ND O. 12 
9. F 63 1.65 0.90 2.95 ND 0.20 
10. M 50 10.10 8.70 3.35 ND 0.11 
Mean + SEM 54 3.92 2.99 2.18 0.78 0.32 
0.97 0.83 0.37 0.19 0.10 
10.7 
1.6 
10.6 
3.5 
6.6 
2.1 
Cholestyramine-treated: 
1 I. F 40 0.29 55.1 
12. F 43 14.50 I 1.60 ND ND 0.13 33.6 
13. F 35 8.35 5.40 ND ND 0.25 26.6 
14. F 37 3.95 2.70 ND ND 0,48 125.2 
15. F 45 2.25 4.50 ND ND 0.21 35.7 
16. F 64 3.85 3.00 ND ND O. 16 48.4 
Mean + SEM 44 6.58 5.44 0.25 54.1 
1.99 1.44 0.05 13.5 b 
Chenodeoxycholic a id-treated: 
17. F 38 1.75 9.10 ND 0.44 0.86 2.0 
18. F 22 1.25 31.20 ND 2.40 0.20 < 0.1 
19. F 55 1.95 52.80 ND 3.92 0.49 < 0.1 
20. F 38 1.05 4.20 ND 0.56 0.25 < O. 1 
21. M 53 0.85 6.20 ND 0.56 0.29 0.2 
Mean _+ SEM 41 1.37 20.70 1.58 __, 0.42 0.4 
0.19 8.40 b 0.61 0.11 0.3 ~ 
CA, cholic acid: CDCA, chenodeoxycholic a id; DCA, deoxycholic acid; UDCA, ursodeoxycholic a id; LCA, lithocholic acid; PV, portal venous; V, 
systemic venous: f, estimated fractional uptake: F, female; M, male; ND, not detected. 
~' Significantly different from untreated, P < 0.05; h < 0.02. 
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patients (nos. 5, 8, 11 and 14) had a non-functioning gall 
bladder as judged by the preoperative cholecystogram 
and/or evidence of impacted stones in the neck of the 
cystic duct at operation. Six of the patients were being 
treated with cholestyramine (Questran ®) in a daily dose of 
16 g for 3 wk prior to surgery. Five of the patients were 
treated with chenodeoxycholic acid (Chenofalk) (15 mg/kg 
body wt. per day) for 3 wk before operation. The medica- 
tion was given in 2 divided doses and was well tolerated in 
all patients. 
Informed consent was obtained from each patient, and 
the ethical aspects of the study were approved by the 
Ethical Committee at Karolinska Institute, Stockholm. 
2.3. Experimental procedure 
The patients were admitted to the hospital on the day 
before operation and were given the regular hospital diet. 
To prevent possible influence of any diurnal variation, 
cholecystectomy was always performed between 8 and 10 
a.m. after a 12-h fast. After access to the biliary tract had 
been obtained, the cystic duct was identified and clamped. 
Portal blood was obtained with direct puncture, and pe- 
ripheral blood was sampled simultaneously from an ante- 
cubital vein [6]. In most of the patients a biopsy specimen 
weighing 2-4 g was taken from the left lobe of the liver. A 
small portion of the tissue sample was sent for histological 
examination, whereas the remainder was immediately put 
into ice-cold homogenizing buffer and rapidly transported 
to the laboratory. A routine cholecystectomy was then 
performed without complications. 
2.4. Serum analysis 
After clotting of the blood at room temperature, serum 
was obtained by centrifugation and frozen at -20°C for 
later analysis. For analysis of lithocholic acid, 100 ng of 
the internal standard, [24-14C]lithocholic a id, dissolved in 
20 txl of ethanol was added to the serum sample, 0.5 ml 
(Fig. 1). The serum together with the internal standard was 
diluted with 2 ml of aqueous ethanol (1:1, v /v )  and 
potassium hydroxide, 500 mg, was added. The mixture 
was left for hydrolysis at 120°C for 16 h. The hydrolyzed 
mixture was diluted with saline and extracted twice with 
diethylether to remove neutral steroids. After acidification 
with hydrochloric acid, the bile acids were extracted with 
diethylether. Bile acids in the ether phase were methylated 
with diazomethane. The methylated extract was converted 
into trimethylsilyl derivative with trichlorosilane, and hex- 
amethylsilazane. The silylated mixture was evaporated to 
dryness and the derivative was finally dissolved in hexane, 
100 txl. This solution, 1 or 2 ~1, was subjected to analysis 
by gas chromatography-mass spectrometry (GC-MS), us- 
ing a Nermag R10-10H instrument. A Delsi DI200 gas 
chromatograph with a split/splitless injection system was 
used. The column was a 15 m, 0.25 mm id fused silica 
Serum, 0.5 ml + 24-14C-Lithocholic a id, 100 ng 
,L 
Alkaline hydrolysis 
l 
Ether extraction from 
acid water phase 
Silylation 
GC-MS with use of molecular 
ions at m/z 372 and m/z 374 
Fig. 1. Analysis of lithocholic acid in human serum. 
column coated with a 0.25 p~m layer of cross-linked 
methyl sililcone, DB-1 or a 30 m 0.25 mm id fused silica 
column coated with 0.25 txm layer of 50% trifluoropropyl, 
DB-210. The initial temperature was 80°C during 1 rain 
and was then increased at a rate of 20°C/min, then further 
increased to 280°C at a rate of 5°C/min. The final temper- 
ature was held at 280°C for 10 min to complete the run. 
The injector and the interface was held at 265°C during the 
analysis. The electron energy was 70 eV. 
Lithocholic acid was quantitated by selected ion moni- 
toring, using the M-90 ions of the trimethylsilyl ether of 
unlabeled and 14C-labeled lithocholic acid (m/z 372 and 
m/z  374, respectively). The ratio between the heights of 
the peaks corresponding to unlabeled and labeled litho- 
cholic acid was compared to a standard curve. The latter 
was obtained by analysis of increasing amounts of unla- 
beled lithocholic acid together with 100 ng of laC-labeled 
lithocholic acid. 
In addition to analysis of unsulfated lithocholic acid, 
cholic acid, chenodeoxycholic acid as well as deoxycholic 
acid were assayed by gas chromatography-mass spectrom- 
etry in the serum samples using deuterium-labeled internal 
standards [7,8] according to a previous modification [9]. 
Ursodeoxycholic a id was analyzed by the same technique 
as described previously [10]. It should be pointed out that 
in contrast to lithocholic acid, neglible amounts of sulfated 
di- and trihydroxylated bile acids are present in the circula- 
tion [ 1 ]. 
2.5. Assay of cholesterol 7u-hydroxylase activity 
The liver biopsy specimen brought to the laboratory 
was minced and homogenized in a Potter-Elvehjem ho- 
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mogenizer with a loosely fitting Teflon pestle. The liver 
homogenate (10% w/v)  was prepared in 9 vol of 50 mM 
Tris HC1 buffer, pH 7.4, containing 50 mM NaC1, 0.3 M 
sucrose, 10 mM ethylenediaminetetraacetic acid, and 10 
mM dithiothreitol. The microsomal fraction was then pre- 
pared by centrifugation technique as described [3]. The 
resulting microsomal fraction was suspended in 0.1 M 
phosphate buffer, pH 7.4, containing 1 mM ethylenedi- 
aminetetraacetic acid, to give a final concentration of 10% 
(w/v).  The microsomal content of protein was determined 
by the method of Lowry et al. [11]. The cholesterol 
7ot-hydroxylase activity was then assayed as described 
previously [3]. The amount of 7a-hydroxycholesterol 
formed during incubation was analyzed by gas-liquid chro- 
matography-mass pectrometry technique and was ex- 
pressed as pmol/min per mg protein [12]. 
2.6. Statistical analysis 
Data are given as mean ___ SEM. The statistical signifi- 
cance of differences were evaluated with the Mann-Whit- 
ney U test and Wilcoxon's matched-pair test. Correlations 
were tested by calculating Spearman's rank-order correla- 
tion coefficient. 
3. Results 
3.1. Assay of unsulfated lithocholic acid by isotope dilu- 
tion-mass pectrometry 
As expected the ratio between the peaks in the tracing 
of m/z  372 and m/z  374 was not linear with the concen- 
tration of unlabeled lithocholic acid in the range 0-2 
Ixmol/1 depending on the natural abundance of [laC]litho- 
cholic acid in unlabeled lithocholic acid. After correction 
for this, a linear standard curve was obtained. Under the 
conditions employed (cf. Section 2), accurate measure- 
ments could be performed with serum levels of lithocholic 
acid higher than 0.05 ixmol/l. When higher sensitivity 
was needed, this could be obtained by increasing the 
amount of internal standard or increasing the amount of 
serum. 
The coefficient of variation of the analysis varied be- 
tween 6% and 13% in the measuring range. The accuracy 
of the method was tested by addition of lithocholic acid, 
0.25 ixmol/1 to a serum sample containing 0.10 _+ 0.01 
Ixmol/1 (mean _+ SD, n = 3). Analysis of the mixture gave 
0.32 _+ 0.02 i.~mol/1. Addition of the taurine conjugate of 
lithocholic acid, 0.25 txmol/1, to the same serum gave 
0.30 + 0.04 txmol/1. 
It should be pointed out that the present method does 
not measure the sulfated form of lithocholic acid. Several 
attempts were made to measure the total amounts of 
lithocholic acid by solvolysis of the serum samples prior to 
alkaline hydrolysis and analysis by the present method. 
The results were however considerably less reproducible 
and more materials than available were required for a safe 
analysis. 
3.2. Unsulfated lithocholic acid in peripheral venous and 
portal venous serum 
The concentration of unsulfated lithocholic acid in pe- 
ripheal venous serum from 7 untreated gallstone patients 
varied from 0.01 ixmol/1 to 0.10 ~mol/ l ,  the average 
concentration being 0.05 ~zmol/1 (Table 1). In portal 
venous serum the concentration of lithocholic acid varied 
from 0.10 Ixmol/1 to 1.23 Ixmol/1, the mean concentra- 
tion being 0.32 ixmol/1 (Tables 1 and 2). Unsulfated 
lithocholic acid constituted about 4% of the total amount 
of portal bile acids analyzed (cholic acid, chenodeoxy- 
cholic acid, deoxycholic acid, ursodeoxycholic acid, and 
lithocholic acid). There was no significant correlation be- 
tween the portal venous concentrations of unsulfated litho- 
cholic acid and chenodeoxycholic a id. 
3.3. Estimated hepatic uptake of individual bile acids 
For unsulfated lithocholic acid, as well as for the other 
bile acids, there was a several-fold higher concentration i
portal venous serum than in peripheral venous serum, 
indicating an hepatic uptake (Table I). The fractional 
uptake of the bile acids has been calculated as f = (0.75 × 
PV + 0.25 x V-V)/(0.75 × PV + 0.25 x V) where f is the 
fractional extraction, PV the portal venous, and V the 
peripheral venous concentration. As seen in Table 1, this 
estimated fractional uptake was 78 + 7% for lithocholic 
acid, similar to that of cholic acid (76 ___ 4%). In this 
calculation, however, only unsulfated lithocholic acid is 
taken into account. If sulfated lithocholic acid that may be 
present in the circulation is taken into account, the frac- 
tional uptake must be lower. The estimated fractional 
uptake of chenodeoxycholic acid (62 + 6%) and deoxy- 
cholic acid (61 ___ 5%) were significantly lower than that of 
cholic acid (P  < 0.05). In the case of cholic acid, chen- 
odeoxycholic acid and deoxycholic acid the degree of 
sulfatation is neglible [1]. 
3.4. Unsulfated lithocholic acid in portal venous serum of 
cholestyramine and chenodeoxycholic acid-treated gall- 
stone patients 
The results are summarized in Table 2. In 6 cholestyra- 
mine-treated patients, the concentration of lithocholic acid 
in portal venous serum varied from 0.13 to 0.48 ixmol/l, 
the mean value being 0.25 Ixmol/1. No detectable amounts 
of deoxycholic acid and ursodeoxycholic a id were found. 
Unsulfated lithocholic acid constituted about 3% of the 
total bile acids (cholic acid, chenodeoxycholic a id and 
lithocholic acid). 
In 5 chenodeoxycholic acid-treated patients, this bile 
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acid became the dominating bile acid. No detectable 
amounts of deoxycholic acid were found. Ursodeoxycholic 
acid constituted about 7% of the total bile acids. The 
concentration of lithocholic acid averaged 0.42 p, mol/1 
(range 0.20-0.80 p~mol/l) and was not significantly dif- 
ferent from that of untreated patients. Lithocholic acid 
constituted about 3% of the total bile acids. 
There was no significant correlation between the portal 
venous concentrations of unsulfated lithocholic acid and 
chenodeoxycholic a id in any of the separate groups of 
patients - -  untreated, cholestyramine-treated, chenodeoxy- 
cholic acid-treated - - nor in the total series of patients. 
3.5. Correlation between portal venous concentration of 
unsulfated lithocholic acid and hepatic cholesterol 7a-hy- 
droxylase activity 
In 4 untreated gallstone patients, the cholesterol 7o~-hy- 
droxylase activity averaged 6.6 ___ 2.1 pmol/min per mg 
protein (Table 2). Treatment with cholestyramine increased 
the enzyme activity several-fold. Treatment with chen- 
odexycholic acid, on the other hand, resulted in a marked 
reduction of the cholesterol 7a-hydroxylase activity. 
When cholesterol 7ot-hydroxylase activity was plotted 
against he portal venous concentration f unsulfated litho- 
cholic acid, no significant correlation was observed in the 
total series of patients (Fig. 2). 
4. Discussion 
Lithocholic acid is a minor bile acid in human serum 
and bile. The present method for analysis of unsulfated 
140 • 
lithocholic acid should have sufficient sensitivity, accuracy 
and precision for the pesent ype of study. Since a rela- 
tively high amount of lithocholic acid in serum is sulfated, 
it would have been an advantage to include also measure- 
ments of sulfated lithocholic acid in the study. The lower 
reproducibility of the latter analysis and lack of material 
prevented us however from such an expansion of the 
study. Since sulfated bile acids are poorly absorbed from 
the intestine and rapidly excreted in faeces, very little 
sulfated lithocholic acid can be expected to be present in 
portal blood. Since the major aim of the present work was 
to study the possibility that the flux of lithocholic acid 
from the intestine to the liver might affect cholesterol 
7ot-hydroxylase activity, the method used here should be 
suitable. 
In the present study, the concentration of lithocholic 
acid in portal venous serum has been determined in hu- 
mans for the first time. Portal venous blood was sampled 
from healthy gallstone patients undergoing cholecystec- 
tomy. Detectable amounts of unsulfated lithocholic acid 
were found in all 10 untreated patients investigated. The 
mean value, 0.32 ixmol/1 constituted about 4% of total 
portal bile acids. This proportion of lithocholic acid is in 
agreement with that reported for bile [ 1,2]. These data give 
further evidence that there exists an enterohepatic circula- 
tion of endogenously formed lithocholic acid in humans 
[13]. 
The concentration of unsulfated lithocholic acid was 
several times higher in portal venous than in peripheral 
venous serum, indicating an hepatic extraction of the bile 
acid. This is in good agreement with previous studies by 
Cowen et al. [14,15]. These authors found that intra- 
venously administered radiolabeled lithocholic acid was 
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rapidly excreted in bile, mostly as sulfated conjugates. 
Labeled lithocholic acid conjugated and/or sulfated rapidly 
disappeared from plasma, probably being cleared by the 
liver. In the present study the hepatic uptake of lithocholic 
acid has been directly measured for the first time in 
humans. The apparent uptake of lithocholic acid was calcu- 
lated to be 78%. It should be pointed out, however, that 
this value was calculated from measurements of unconju- 
gated, glycine conjugated and taurine conjugated bile acid 
and sulfated lithocholic acid was not taken into account. If 
it had been possible to measure also sulfated lithocholic 
acid, the fractional uptake would have been lower. The 
hepatic uptake of the dihydroxy bile acids, chenodeoxy- 
cholic acid (62%), and deoxycholic acid (61%) were lower 
than that of cholic acid. These results are in good agree- 
ment with previous results [6,8]. 
The most important finding of the present study is that 
the portal venous concentration of unsulfated lithocholic 
acid does not seem to significantly influence the choles- 
terol 7ct-hydroxylase activity. According to current opin- 
ions, the portal inflow of bile acids is of regulatory impor- 
tance for bile acid synthesis in the liver [3,4]. In a recent 
study we found that not only the total concentration of bile 
acids in the portal venous serum but also the pattern of 
individul bile acids seems of importance [3]. Thus, treat- 
ment with chenodeoxycholic a id caused a marked inhibi- 
tion of cholesterol 7c~-hydroxylase activity, whereas ur- 
sodeoxycholic acid, being a more hydrophilic bile acid 
than chenodeoxycholic a id, did not. A significant correla- 
tion between the concentration of chenodeoxycholic a id 
in portal venous serum and the cholesterol 7ct-hydroxylase 
activity was obtained. Recently Hall et al. [5] gave evi- 
dence that small amounts of monohydroxy bile acids are of 
regulatory importance for bile acid synthesis in rabbits, 
and they proposed that this may be the case also in 
humans. To evaluate such a possible regulatory role of 
lithocholic acid, the portal venous concentration of unsul- 
fated lithocholic acid was determined in gallstone patients 
with a wide range of cholesterol 7c~-hydroxylase activities 
- -  untreated patients, cholestyramine-treated patients with 
a several-fold increased enzyme activity, and chenodeoxy- 
cholic acid-treated patients with a markedly suppressed 
cholesterol 7ct-hydroxylase activitiy. No significant corre- 
lation between unsulfated lithocholic acid concentrations 
in portal venous serum and hepatic holesterol 7c~-hydrox- 
ylase activities was obtained, however. Since little or no 
sulfated lithocholic acid can be expected to be present in 
portal blood (cf. above), the methodological limitation is 
not likely to be important for the conclusions. 
It should be emphasized that all data of the present 
study represent the fasting state. Only fasting samples of 
the venous blood were analysed with respect o concentra- 
tions of individual bile acids. There is some evidence that 
the postprandial bile acid inflow to the liver may be more 
important as a regulator to bile acid biosynthesis than the 
fasting level [ 16]. 
It has previously been reported that treatment with 
chenodeoxycholic acid is associated with an increased 
proportion of lithocholic acid in biliary bile acids and an 
increased concentration i  serum of peripheral blood of 
gallstone patients [17,18]. In the present study, the portal 
venous concentration of unsulfated lithocholic acid tended 
to be higher in the chenodeoxycholic a id-treated patients 
compared with the untreated, but the difference did not 
reach statistical significance. We could not find any signif- 
icant correlation between the portal venous concentrations 
of lithocholic acid and chenodeoxycholic a id. Hypotheti- 
cally, an accumulation of lithocholic acid in the circulating 
bile acids might be due to defective sulfation of lithocholic 
acid. However, according to several studies, the per cent 
sulfation of lithocholic acid remains to be unchanged 
during treatment with chenodeoxycholic a id [18-20]. 
To conclude, our study confirms an enterohepatic circu- 
lation of lithocholic acid in humans. Unsulfated lithocholic 
acid constitutes about 4% of the total bile acids in the 
portal venous blood. No evidence was obtained to indicate 
that the portal inflow of small amounts of lithocholic acid 
is of any major regulatory importance for the hepatic 
cholesterol 7c~-hydroxylase activity. 
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